NEWS | alsv | Page 2 of 15

Companies in the News

Generate Biomedicines Announces Raise of $370 Million to Advance its Drug Generation Platform

Cambridge, Mass, November 18, 2021 – Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent...

Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation

Tessera’s Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their...

Laronde banks $440M to ramp up RNA-based meds that could turn cells into protein factories

Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years....

Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases

Redefining neuroscience research and development with a data-driven precision neuroscience platform to develop targeted therapies for...

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company

Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW SAN DIEGO,...

BiotechBayer bets $1.5B that Vividion will help it target the 'undruggable' and make 1+1=3

Sometimes, it takes $1.5 billion to make "one plus one equal three." Bayer wanted to "really transform" its R&D engine under its recently...

Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform

Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible...

Pacific Biosciences Signs Definitive Agreement to Acquire Omniome

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets...

Vividion Therapeutics Files for IPO

Vividion Therapeutics Inc., a biotechnology company that seeks to develop drugs for cancer and immune disorders using "traditionally...